OPEN END TURBO SHORT - IONIS PHARMACEUTICALS Share Price

Certificat

DE000ME92787

Market Closed - Börse Stuttgart 19:49:45 29/05/2024 BST
1.29 EUR +11.21% Intraday chart for OPEN END TURBO SHORT - IONIS PHARMACEUTICALS
Current month+53.57%
1 month+61.25%
Date Price Change
29/05/24 1.29 +11.21%
28/05/24 1.16 -0.85%
27/05/24 1.17 -2.50%
24/05/24 1.2 +4.35%
23/05/24 1.15 +1.77%

Delayed Quote Börse Stuttgart

Last update May 29, 2024 at 07:49 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellPUT
Underlying IONIS PHARMACEUTICALS, INC.
Issuer Morgan Stanley
WKN ME9278
ISINDE000ME92787
Date issued 21/02/2024
Strike 50.11 $
Maturity Unlimited
Parity 10 : 1
Emission price 0.53
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 1.29
Lowest since issue 0.29

Company Profile

Ionis Pharmaceuticals, Inc. is engaged in ribonucleic acid (RNA)-targeted therapeutics. The Company has five marketed medicines and a pipeline in neurology, cardiology, and other areas of high patient need. It has nine medicines in Phase III development and multiple additional medicines in early and mid-stage development. The Company’s products include SPINRAZA, QALSODY, WAINUA, TEGSEDI and WAYLIVRA. SPINRAZA is used for the treatment of patients with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. QALSODY is an antisense medicine that is used for the treatment of adult patients with superoxide dismutase 1 amyotrophic lateral sclerosis (SOD1-ALS), a rare, neurodegenerative disorder that causes progressive loss of motor neurons leading to death. WAINUA is a self-administered subcutaneous LIgand-Conjugated Antisense (LICA) medicine used for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis (ATTRv-PN).
Sector
-
More about the company

Ratings for Ionis Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Ionis Pharmaceuticals, Inc.

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
36.45 USD
Average target price
57.95 USD
Spread / Average Target
+58.98%
Consensus